Kolon Life Science

Activity by year

201820192020202120222023202420252026

Contract

Nov 19, 2018CONTRACTJapan$591.6M
Mundipharma wins contract to launch Kolon's Invossa in Japan
Mundipharma won an exclusive technology export contract from Kolon Life Science to launch Invossa, a cell-mediated gene therapy for degenerative arthritis, in Japan. The contract is effective for 15 years after launch, with a total value of $591.6 million.
Kolon Life Science supplier Mundipharma customer #Medical Devices ajupress.com
Jul 18, 2018CONTRACTHainan Province, China$200.0M
Kolon Life Science signs $200M supply deal for osteoarthritis drug Invossa-K
Kolon Life Science signed a 230 billion won ($200 million) contract to supply its osteoarthritis drug Invossa-K to China Life Medical Centre in Hainan Province, China. The contract was announced on July 18, 2018.
Kolon Life Science China Life Medical Centre customer biz.heraldcorp.com pulse.mk.co.kr
Jun 20, 2018CONTRACTHong Kong and Macau, Hong Kong SAR China$15.0M
Kolon Life Science signs KRW 16.9B supply deal for Invossa-K
Kolon Life Science has signed a 16.9 billion won supply contract with Zhong JI 1 International Medical Group for Invossa-K in Hong Kong and Macau. The contract is for five years.
Kolon Life Science Zhong JI 1 International Medical Group customer #Medical Devices etoday.co.kr

Customers

Loading…